About Serina Therapeutics, Inc.
https://serinatherapeutics.comSerina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy.
CEO
Steven A. Ledger
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-15 | Reverse | 7:250 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:180.01K
Value:$480.63K
BROADWOOD CAPITAL INC
Shares:83.19K
Value:$222.13K
WAVERLY ADVISORS, LLC
Shares:67.49K
Value:$180.2K
Summary
Showing Top 3 of 27
About Serina Therapeutics, Inc.
https://serinatherapeutics.comSerina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $6.38M ▲ | $-4.58M ▲ | 0% ▲ | $-0.44 ▲ | $-4.57M ▲ |
| Q2-2025 | $130K ▲ | $5.68M ▼ | $-6.45M ▼ | -4.96K% ▼ | $-0.64 ▼ | $-6.44M ▼ |
| Q1-2025 | $0 ▲ | $5.84M ▲ | $-4.81M ▼ | 0% ▼ | $-0.49 ▼ | $-4.8M ▼ |
| Q4-2024 | $-14K ▼ | $5.54M ▲ | $-2.74M ▼ | 19.57K% ▲ | $-0.31 ▼ | $-2.68M ▼ |
| Q3-2024 | $14K | $5.33M | $1.41M | 10.07K% | $0.16 | $1.45M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $8.62M ▲ | $12.41M ▲ | $10.82M ▲ | $1.76M ▼ |
| Q2-2025 | $6.04M ▲ | $8.94M ▲ | $7.29M ▲ | $1.8M ▲ |
| Q1-2025 | $4.27M ▲ | $6.73M ▲ | $5.17M ▼ | $1.7M ▲ |
| Q4-2024 | $3.67M ▲ | $6.72M ▼ | $6.22M ▼ | $641K ▲ |
| Q3-2024 | $3.19M | $7.43M | $21.26M | $-13.77M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-4.58M ▲ | $-3.85M ▼ | $-13K ▲ | $6.44M ▲ | $2.58M ▲ | $-3.86M ▼ |
| Q2-2025 | $-6.46M ▼ | $-3.75M ▲ | $-46K ▼ | $5.57M ▲ | $1.77M ▲ | $-3.75M ▲ |
| Q1-2025 | $-4.82M ▼ | $-4.32M ▲ | $0 ▲ | $4.92M ▼ | $595K ▲ | $-4.32M ▲ |
| Q4-2024 | $-2.75M ▼ | $-4.59M ▼ | $-5K ▼ | $5.03M ▲ | $437K ▲ | $-4.59M ▼ |
| Q3-2024 | $1.38M | $-2.96M | $-3K | $86K | $-2.88M | $-2.96M |
CEO
Steven A. Ledger
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-15 | Reverse | 7:250 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:180.01K
Value:$480.63K
BROADWOOD CAPITAL INC
Shares:83.19K
Value:$222.13K
WAVERLY ADVISORS, LLC
Shares:67.49K
Value:$180.2K
Summary
Showing Top 3 of 27